Literature DB >> 17997703

WHI and WHIMS follow-up and human studies of soy isoflavones on cognition.

Liqin Zhao1, Roberta Diaz Brinton.   

Abstract

Recent follow-up analyses of the previous findings from the Women's Health Initiative and the Women's Health Initiative Memory Study confirmed some health benefits of estrogen-containing hormone therapy (HT) in women within 10 years from the onset of menopause. However, the potential risks associated with long-term administration of HT, such as breast cancer and stroke, remain a concern for therapy recipients, underlying the need for an alternative treatment that is functionally equivalent but with a greater safety profile. Owing to their structural and functional resemblance to mammalian estrogens and lack of evident adverse effects, research interest in plant-derived phytoestrogens has increased in the past decade. While multiple health-promoting benefits of phytoestrogens have been proposed from basic science, the clinical data remain inconclusive. This review provides a comparative analysis of human studies on the effects of soy-based isoflavones on cognition. Of the eight studies published in 2000-2007, seven were conducted in postmenopausal women, four of which revealed a positive impact of isoflavones on cognitive function. Multiple factors could have contributed to the discrepant outcomes across studies, such as variation in the composition of phytoestrogen interventions and the heterogeneous characteristics of the study population. Thus, a well-designed clinical study based on a standardized stable formulation in a well-characterized study population is required in order to reach a clinical consensus. A formulation composed of select estrogen receptor beta-selective phytoestrogens with a rationally designed composition would avoid the potential antagonism present in a mixture and thus enhance therapeutic efficacy. In addition, inclusion of equol in a study formulation offers a potential synergistic effect from equol in both equol-producing and nonproducing individuals, as well as added benefits for men. With respect to the design of study population, a clinically consistent effect could potentially be achieved by stratifying populations based on genotype, age, hormonal history and even diets. Development of an effective phytoestrogen formulation would benefit both women and men to prevent or treat hormone-dependent conditions and, most of all, to improve neurological health and reduce the risk of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997703     DOI: 10.1586/14737175.7.11.1549

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  29 in total

1.  Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease.

Authors:  Sonia George; Géraldine H Petit; Gunnar K Gouras; Patrik Brundin; Roger Olsson
Journal:  ACS Chem Neurosci       Date:  2013-09-25       Impact factor: 4.418

2.  Dairy, soy, and calcium consumption and risk of cognitive impairment: the Singapore Chinese Health Study.

Authors:  Mohammad Talaei; Lei Feng; Jian-Min Yuan; An Pan; Woon-Puay Koh
Journal:  Eur J Nutr       Date:  2019-06-03       Impact factor: 5.614

3.  Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial.

Authors:  Lon S Schneider; Gerson Hernandez; Liqin Zhao; Adrian A Franke; Yu-Ling Chen; Sonia Pawluczyk; Wendy J Mack; Roberta D Brinton
Journal:  Menopause       Date:  2019-08       Impact factor: 2.953

4.  Low dietary soy isoflavonoids increase hippocampal spine synapse density in ovariectomized rats.

Authors:  Neil J MacLusky; Gladis Thomas; Csaba Leranth
Journal:  Brain Res       Date:  2017-01-04       Impact factor: 3.252

5.  Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy.

Authors:  Yiwei Wang; Gerson Hernandez; Wendy J Mack; Lon S Schneider; Fei Yin; Roberta D Brinton
Journal:  Menopause       Date:  2020-01       Impact factor: 2.953

Review 6.  Estrogen-induced plasticity from cells to circuits: predictions for cognitive function.

Authors:  Roberta Diaz Brinton
Journal:  Trends Pharmacol Sci       Date:  2009-03-18       Impact factor: 14.819

7.  Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments.

Authors:  Jia Yao; Liqin Zhao; Zisu Mao; Shuhua Chen; Karren Carmen Wong; Jimmy To; Roberta Diaz Brinton
Journal:  Brain Res       Date:  2013-02-18       Impact factor: 3.252

Review 8.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

9.  17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.

Authors:  Liqin Zhao; Jia Yao; Zisu Mao; Shuhua Chen; Yan Wang; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2010-01-06       Impact factor: 4.673

10.  The effects of dietary treatment with S-equol on learning and memory processes in middle-aged ovariectomized rats.

Authors:  Steven L Neese; Samantha L Pisani; Daniel R Doerge; William G Helferich; Estatira Sepehr; Amar G Chittiboyina; Sateesh Chandra Kumar Rotte; Troy J Smillie; Ikhlas A Khan; Donna L Korol; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2013-12-22       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.